{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Per International Myeloma Working Group (IMWG) Uniform Response Criteria guidelines as assessed by laboratory blood tests: Complete Response (CR), negative immunofixation of serum and urine, disappearance of soft tissue plasmacytomas, \\<5% plasma cells in bone marrow; Stringent Complete Response (sCR), same as CR plus normal serum free light chain (FLC) ratio and absence of clonal plasma cells; Very Good Partial Response (VGPR), serum and urine M-component still detectable by immunofixation or \\>/= 90% reduction in serum M-component plus a urine M component of, 100mg per 24hrs; Partial Response (PR) ≥ 50% reduction of the serum M-protein and 24 hour urinary M-protein by ≥ 90%, or to \\< 200 mg per 24 hours. If serum and urine M-protein are not measurable, a ≥ 50% decrease in the difference between involved and uninvolved FLC levels is required OR If FLC is also not informative, ≥ 50% reduction in bone marrow plasma. ORR includes following only: CR+sCR+VGPR+PR","groups":[{"description":"Combination of cabozantinib, carfilzomib and dexamethasone\n\nCabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.\n\nCabozantinib: Phase I: Level -1 = 20 mg\n\nCarfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16\n\nDexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)","id":"OG000","title":"Level -1 = 20 mg"},{"description":"Combination of cabozantinib, carfilzomib and dexamethasone\n\nCabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.\n\nCabozantinib: Phase I: Level 0 = 40 mg\n\nCarfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16\n\nDexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)","id":"OG001","title":"Level 0 = 40 mg"},{"description":"Combination of cabozantinib, carfilzomib and dexamethasone\n\nCabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.\n\nCabozantinib: Phase I: Level +1 = 60 mg\n\nCarfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16\n\nDexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)","id":"OG002","title":"Level +1 = 60 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Two subjects were not included in this analysis as the protocol states that an individual must complete at least 2 cycles before a best response (ORR) could be established.","reportingStatus":"POSTED","timeFrame":"2 cycles (approximately 56 days)","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Participants"}